Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469937 · ClinicalTrials.gov registry record · Phase 1
Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases
A Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00469937 is a Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 9 participants.
The verdict
NCT00469937, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as lithium, may protect normal cells from the side effects of radiation therapy. Giving lithium together with radiation therapy may allow a higher dose of radiation therapy to be given so that more tumor cells are killed. PURPOSE: This phase I trial is studying the side effects and best dose of lithium when given together with whole-brain radiation therapy in treating patients with brain metastases from primary cancer outside the brain.
Interventions
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- PROCEDURE cognitive assessment
- DRUG lithium carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469937
The ClinicalTrials.gov registry entry for NCT00469937 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which quality-of-life assessment is the first listed.
NCT00469937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00469937 about?
NCT00469937 is a clinical study titled "Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as lithium, may protect normal cells from the side effects of radiation therapy. Giving lithium together with radiation therapy may allow a higher dose of radiation therapy to be given so that more tumor cells are ...
What is the current status of trial NCT00469937?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-02. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00469937?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), cognitive assessment (PROCEDURE), lithium carbonate (DRUG).
Who is sponsoring clinical trial NCT00469937?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.